Screener
PBE vs XBI
Invesco Biotechnology & Genome ETF vs State Street SPDR S&P Biotech ETF
Key differences
- XBI costs 0.23% less per year.
- XBI is significantly larger than PBE — larger funds tend to be more liquid and less likely to close.
- Over the last 3 years, XBI has delivered higher annualized returns.
Side-by-side comparison
| PBE | XBI | |
|---|---|---|
| Annual cost (TER) | 0.58% | 0.35% |
| Fund size (AUM) | $247M | $8.3B |
| Since | 2005 | 2006 |
| Dividend yield | 1.09% | 0.34% |
| Asset class | equity | equity |
| Region | north america | north america |
| Strategy | index tracking | index tracking |
| CAGR 1Y | +34.1% | +66.6% |
| CAGR 3Y | +10.3% | +15.6% |
| CAGR 5Y | +3.3% | +0.9% |
| Sharpe 3Y | 0.41 | 0.54 |
| Volatility 1Y | 18.63% | 25.14% |
| Max drawdown | -37.84% | -63.89% |
Green dot indicates the better value for that metric. Performance data is historical and does not predict future results.
Similar to PBE and XBI
Explore further